Pharmacology

Antibiotics: connect the target to the infection

Choose antibiotics by bacterial target, infection site, resistance and patient risk, then apply those distinctions to treatment and adverse effects.

A culture says susceptible, but the patient still needs the right drug in the right compartment. Antibiotic selection starts with a suspected organism and its vulnerable structure, then accounts for infection site, severity, resistance, allergy history and drug exposure. A wider spectrum cannot repair an undrained abscess or compensate for poor tissue penetration.

The common misconception is that drugs within a class are interchangeable. Ceftriaxone and ceftazidime share a generation, yet their useful coverage differs. Vancomycin given orally and intravenously serves different purposes. Learn each exception at the decision where it matters.

Picture the target before naming the drug

Typical Gram-positive bacteria have thick peptidoglycan outside one cytoplasmic membrane. Typical Gram-negative bacteria have a thinner peptidoglycan layer between inner and outer membranes; the outer membrane contains LPS and can restrict antibiotic entry. Porins and transport systems therefore matter alongside the molecular target. Mycoplasma lacks peptidoglycan rather than merely having a thin wall. [38] [43]

Beta-lactams bind penicillin-binding proteins, including transpeptidases, and impair peptidoglycan cross-linking. Vancomycin binds the D-alanyl-D-alanine ends of cell-wall precursors instead. The destination is similar; the molecular binding partner is different. That distinction explains why an altered PBP and an altered terminal peptide produce different resistance patterns. Mycoplasma has no peptidoglycan wall, so neither strategy gives useful treatment. Legionella is a different problem: its intracellular location favors agents with appropriate cellular activity, rather than an assertion that all atypical organisms lack walls. [11] [24] [9]

Bacterial targets, arranged from the exterior to the cytoplasm

Cell envelope

PBPs: beta-lactams. Wall precursor ends: vancomycin. Membrane integrity: daptomycin for Gram-positive organisms; polymyxins for selected Gram-negative organisms.

Ribosome inside the cell

30S: aminoglycosides disrupt accurate translation; tetracyclines prevent aminoacyl-tRNA access. 50S: macrolides, clindamycin and chloramphenicol interrupt different translation steps; linezolid prevents a functional initiation complex.

Nucleic acids and precursor supply

Fluoroquinolones inhibit DNA gyrase and topoisomerase IV. Activated metronidazole products damage DNA. Rifampin inhibits bacterial RNA polymerase. Sulfonamides and trimethoprim interrupt successive folate-synthesis reactions.

Position identifies the target, not a guarantee of spectrum. The envelope, uptake systems and acquired resistance determine whether the drug reaches that target. [33] [31] [12]

Aminoglycoside uptake requires energy-dependent transport and is ineffective against obligate anaerobes. Their concentration-dependent bacterial killing does not make them a safe substitute for every other ribosomal drug. Tetracyclines and fluoroquinolones also bind polyvalent cations in the gut; simultaneous iron, calcium or antacids can reduce oral absorption. Trimethoprim inhibits dihydrofolate reductase while sulfamethoxazole inhibits dihydropteroate synthase. Dapsone also targets bacterial folate synthesis but is used for selected indications, not as general broad-spectrum treatment. [34] [31] [33] [13] [15] [19]

Try it here · Checkpoint 1 of 3

Make your prediction before reading the choices. A first attempt is just a starting point.

Case 1

Show answer and explanations

A. PBP-mediated peptidoglycan cross-linking (Best answer)
Penicillin binds PBPs and impairs transpeptidation, weakening the wall of this susceptible streptococcus.
B. Binding of aminoacyl-tRNA to the 30S subunit (Why this does not fit)
This is the tetracycline target; it does not explain penicillin activity in this infection.
C. Formation of a functional 70S initiation complex (Why this does not fit)
Linezolid binds the 50S subunit and prevents formation of the functional 70S initiation complex. Penicillin acts on the wall.
D. Conversion of dihydrofolate to tetrahydrofolate (Why this does not fit)
Trimethoprim inhibits this reaction. Penicillin does not deplete bacterial folate through that enzyme.

Takeaway: Distinguish a wall enzyme target from a ribosomal or folate target.

Case sources: [24] [12] [31] [15]

Try a question on this topic

A 61-year-old man comes to the emergency department because of 3 days of diffuse muscle aching, difficulty rising from a chair, and dark brown urine. Ten days ago he was seen in clinic for fever and a productive cough, a chest x-ray showed a right lower lobe infiltrate, and he was started on oral clarithromycin. His cough has improved. He has taken simvastatin 40 mg daily for 6 years for elevated LDL cholesterol without prior symptoms and has not exercised strenuously or used alcohol recently. Temperature is 37.1 C, pulse is 92/min, and blood pressure is 134/82 mm Hg. Proximal muscles of the arms and thighs are tender, and strength is 4/5 in the hip flexors. Urine dipstick is strongly positive for blood, but microscopy shows 0 to 2 erythrocytes per high-power field. Laboratory studies show:

Serum
Test	Result
Creatine kinase	23,600 U/L
Creatinine	1.9 mg/dL
Potassium	5.3 mEq/L
AST	310 U/L

Which of the following most likely accounts for this new problem?

Choose an answer before revealing the reasoning.

Get one of these every morning · Practice more in the QBank

Build a spectrum map with named exceptions

Penicillin G treats susceptible streptococci and other specific susceptible organisms. Amoxicillin extends useful activity to selected respiratory organisms; beta-lactamase production can defeat it. Piperacillin-tazobactam adds broad Gram-negative and anaerobic coverage, including susceptible Pseudomonas, but is not dependable definitive treatment for an ESBL bloodstream infection. A beta-lactamase inhibitor protects against some enzymes; it does not erase every resistance mechanism. [1]

Cephalosporins: choose the named agent
Agent or subgroup	Useful distinction	Important gap
Cefazolin	MSSA, streptococci; common surgical prophylaxis agent	MRSA and Pseudomonas
Cefuroxime; cefoxitin	Cefuroxime has respiratory uses; cefoxitin has selected anaerobic activity	Neither supplies dependable Pseudomonas coverage
Ceftriaxone; ceftazidime	Ceftriaxone supports many community infection regimens; ceftazidime covers susceptible Pseudomonas	Ceftriaxone misses Pseudomonas; ceftazidime is weaker for many Gram-positive targets
Cefepime	Broad aerobic coverage including susceptible Pseudomonas	MRSA, enterococci and dependable anaerobic coverage
Ceftaroline; ceftobiprole	MRSA-active cephalosporins with agent-specific indications	Do not extrapolate either drug to every MRSA infection

For uncomplicated clean orthopedic implantation, cefazolin is a standard prophylaxis choice when tolerated; select prophylaxis for the expected operative flora rather than maximal spectrum. [26] Generation numbers do not describe a simple trade of Gram-positive for Gram-negative activity. Ceftaroline is no longer the only MRSA-active cephalosporin: the FDA approved ceftobiprole in 2024, including adult S. aureus bacteremia with right-sided endocarditis. Its CABP indication specifically lists methicillin-susceptible S. aureus, not MRSA. [2] [30]

Meropenem and imipenem can cover susceptible Pseudomonas; ertapenem does not. Aztreonam targets aerobic Gram-negative organisms, leaving Gram-positive and anaerobic gaps. Ciprofloxacin and levofloxacin can cover susceptible Pseudomonas; moxifloxacin is not a reliable antipseudomonal choice and is unsuitable for routine UTI treatment. Macrolides and doxycycline supply atypical respiratory activity. Vancomycin supplies Gram-positive activity, not Gram-negative coverage or reliable treatment of VRE.

Linezolid can treat selected VRE infections. Daptomycin disrupts Gram-positive membranes but is inactivated by pulmonary surfactant, so bloodstream activity does not translate into treatment of alveolar pneumonia. Polymyxin toxicity and newer active alternatives limit its role in resistant Gram-negative disease. [1] [9] [12] [17]

Let the infection site change the prescription

For community-acquired pneumonia, distinguish a stable outpatient from a hospitalized patient and assess comorbidities and resistant-organism risk. In otherwise healthy outpatients, amoxicillin or doxycycline are guideline options; macrolide monotherapy is conditional on local pneumococcal macrolide resistance below 25%. Outpatients with comorbidities such as chronic heart, lung, liver or kidney disease, diabetes, malignancy or asplenia need a different regimen: amoxicillin-clavulanate or a suitable cephalosporin plus a macrolide or doxycycline, or an appropriate respiratory fluoroquinolone alone.

Weigh contraindications and prior exposure. For hospitalized nonsevere CAP without MRSA or Pseudomonas risk, a beta-lactam such as ceftriaxone plus a macrolide or a respiratory fluoroquinolone alone are options. Severe CAP requires combination therapy: a beta-lactam plus a macrolide or respiratory fluoroquinolone. These recommendations concern adults without major immunocompromise. Aspiration alone does not require additional anaerobic therapy unless lung abscess or empyema is suspected.

Hospital-acquired pneumonia needs local susceptibility data and patient-specific resistance assessment, not an automatic three-drug formula. [9] [22]

Suspected bacterial meningitis requires prompt parenteral therapy. Ceftriaxone or cefotaxime forms a common backbone, with additional vancomycin according to pneumococcal resistance guidance. Add ampicillin or amoxicillin when Listeria risk is present; cephalosporins leave this gap. WHO includes older age over 60, pregnancy and immunocompromise among risk factors. In non-epidemic settings where lumbar puncture can be performed, WHO recommends starting adjunctive IV corticosteroid with the first antibiotic dose in suspected acute bacterial meningitis, then reassessing continuation against CSF and microbiology findings.

If lumbar puncture cannot be performed, that recommendation is conditional on strong clinical suspicion and no contraindication. For babies in neonatal units with suspected meningitis and an unknown pathogen, NICE recommends IV amoxicillin plus cefotaxime; refine treatment using microbiology and local neonatal guidance. This is a meningitis regimen, not a general rule for every neonatal fever. [40] Neonates require their own age-specific regimen: do not casually transfer an adult ceftriaxone plan to a jaundiced newborn or one receiving intravenous calcium. [23] [24]

In skin infection, nonpurulent cellulitis usually calls for streptococcal coverage. A drainable abscess needs drainage; systemic illness, host risk and culture findings determine adjunct antibiotics. TMP-SMX and doxycycline can be useful for susceptible MRSA skin infection but are not universal stand-alone choices for nonpurulent cellulitis or invasive bacteremia. Rapidly progressive pain, toxicity and necrosis demand surgical assessment. Once group A streptococcal necrotizing fasciitis is documented, penicillin plus clindamycin supports bacterial killing and toxin suppression alongside surgery. [10]

Separate bladder infection from renal infection and bacteremia. Nitrofurantoin achieves useful urine concentrations but inadequate renal tissue levels for pyelonephritis. Similarly, oral vancomycin acts within the intestinal lumen for C. difficile; intravenous vancomycin does not replace this route. For an initial nonfulminant C. difficile episode, fidaxomicin is preferred when feasible, with oral vancomycin an acceptable alternative.

Fulminant disease has a separate regimen and urgent assessment for complications. Metronidazole is not the default first choice for every episode. Avoid adding it automatically to a carbapenem that already supplies anaerobic coverage. Nitrofurantoin and TMP-SMX, when susceptible and otherwise appropriate, are options for uncomplicated lower UTI even with ESBL-producing organisms; that does not make them interchangeable for renal infection or sepsis. [6] [8] [1]

Metronidazole also treats selected protozoal infections, including Trichomonas, Giardia and invasive Entamoeba histolytica. Amebiasis needs subsequent luminal treatment. In H. pylori infection, metronidazole belongs in an effective combination such as bismuth quadruple therapy, not as a single-agent cure. [5] [35] [36]

Mixed intra-abdominal infection requires coverage of relevant enteric aerobes and anaerobes plus drainage or operative source control when indicated. Cefepime, for example, requires an anaerobic partner such as metronidazole in its labeled intra-abdominal regimen. For localized dental pulpal or periapical disease in an adult without severe immunocompromise, prioritize definitive dental care, including drainage when indicated. Systemic spread changes the need for antibiotics. [18] [39]

Try it here · Checkpoint 2 of 3

Make your prediction before reading the choices. A first attempt is just a starting point.

Case 26

Show answer and explanations

A. Anaerobes are never recovered from aspiration-associated pneumonia (Why this does not fit)
Anaerobes can be involved, especially with abscess or empyema. The guideline does not support this absolute claim.
B. Azithromycin provides comprehensive anaerobic coverage (Why this does not fit)
Azithromycin is not added to a CAP regimen for comprehensive anaerobic treatment; the question is whether extra coverage is indicated.
C. Every aspiration-associated infiltrate is chemical pneumonitis (Why this does not fit)
The stem specifies bacterial pneumonia. Aspiration pneumonitis and bacterial pneumonia require clinical distinction.
D. Aspiration alone does not establish a need for additional anaerobic coverage (Best answer)
The CAP guideline reserves routine additional anaerobic coverage for situations such as suspected abscess or empyema.

Takeaway: Do not equate aspiration history with an automatic anaerobic prescription.

Case sources: [9]

Translate resistance into a treatment decision

Beta-lactamases destroy susceptible beta-lactams. ESBLs commonly defeat third-generation cephalosporins; carbapenems remain preferred for serious ESBL infections outside the urinary tract. In critical illness or hypoalbuminemia, meropenem or imipenem-cilastatin is preferred over ertapenem. The July 2026 IDSA guidance also discusses newer alternatives. Susceptibility, site and severity remain essential even when the laboratory reports an apparently reassuring result. [1]

Change the binding site: mecA-associated PBP2a reduces affinity for most beta-lactams in MRSA. vanA-mediated replacement of D-Ala-D-Ala by D-Ala-D-Lac markedly reduces vancomycin binding. These are distinct from antibiotic destruction. [33] [27] [28]
Modify the ribosome: erm-mediated methylation can cause macrolide-lincosamide-streptogramin B resistance. An erythromycin-resistant, apparently clindamycin-susceptible staphylococcal isolate may need a D-test to expose inducible resistance. [29]
Limit intracellular drug: Efflux pumps expel drugs and porin changes restrict entry. Multiple mechanisms can coexist, especially in resistant Gram-negative organisms.

Start adequate empiric therapy promptly in serious infection, obtain appropriate cultures without harmful delay, and reassess when identification and susceptibility return. High-risk febrile neutropenia requires an intravenous antipseudomonal beta-lactam; routine vancomycin is unnecessary without a specific indication such as hemodynamic instability, catheter infection or pneumonia. Definitive MSSA therapy generally favors an antistaphylococcal beta-lactam when tolerated. Endocarditis, especially involving prosthetic material, needs organism-specific specialist treatment and source-control assessment rather than a single memorized drug. [21] [10]

Oral transition for susceptible resistant Gram-negative infection is possible when the patient is stable, source control is adequate and absorption is reliable. A urine-only agent is not an acceptable bloodstream step-down drug. Enterococcal endocarditis sometimes uses synergistic combinations, including ampicillin plus ceftriaxone in selected E. faecalis infection; synergy does not mean every patient needs an aminoglycoside. For ampicillin-susceptible enterococci, ampicillin may be useful, but invasive endocarditis needs a syndrome-specific combination. Do not transfer E. faecium options to E. faecalis: quinupristin-dalfopristin lacks useful E. faecalis activity. [37] Dose, duration and combination choices belong to the identified syndrome. [25]

Recognize the adverse effect without missing the emergency

Vancomycin can cause rate-related flushing and pruritus, but severe infusion reactions can include hypotension. Stop the infusion and assess airway and circulation before labeling a reaction benign. Anaphylaxis is a competing emergency; isolated flushing during a rapid infusion may permit a slower subsequent infusion after assessment. IV vancomycin also carries kidney-injury risk, requiring exposure and renal monitoring.

Aminoglycosides can cause neuromuscular blockade, especially with neuromuscular blockers or neuromuscular disease. Aminoglycosides can cause renal injury and irreversible auditory or vestibular toxicity; risk rises with excess exposure and other nephrotoxic drugs. Cefepime accumulation can present with confusion, myoclonus or seizures, especially in renal impairment, although appropriate adjustment does not eliminate all risk. Imipenem also has seizure risk, accentuated by excessive exposure or renal/CNS disease; cilastatin inhibits renal dehydropeptidase and protects imipenem from renal metabolism.

Beta-lactam reactions range from rash to anaphylaxis, so characterize the actual reaction before selecting an alternative. [32] [11] [13] [18]

Fluoroquinolone tendon injury is especially concerning with older age and corticosteroid exposure; neuropathy, CNS effects and dysglycemia also affect selection. Aortic aneurysm/dissection is an additional warning, particularly for patients with an aneurysm or major risk factors; use a fluoroquinolone in those patients only when suitable alternatives are unavailable. This is not a claim that every patient develops an aortic injury.

Doxycycline can cause photosensitivity. [31] Erythromycin stimulates motilin receptors and can increase gastrointestinal motility; its CYP3A inhibition can increase exposure to susceptible co-medications. Do not assume every macrolide has an identical interaction profile. [41] [42] Macrolides can prolong QT, particularly with other QT-prolonging drugs or electrolyte deficits. Chloramphenicol carries marrow toxicity and can accumulate in newborns with immature clearance, causing gray syndrome.

TMP-SMX can produce hyperkalemia, particularly with kidney disease or renin-angiotensin system drugs, and serious skin reactions. Hemolysis can occur with G6PD deficiency, and folate-related cytopenias matter in susceptible patients. A rash with mucosal injury needs urgent assessment, not diagnosis from a decorative photograph. [19] [20] [14] [15]

Linezolid can cause thrombocytopenia and has reversible monoamine oxidase inhibition. Review serotonergic medicines and monitor blood counts weekly. Peripheral or optic neuropathy is especially associated with prolonged courses, although visual symptoms can occur earlier; the current label advises monitoring during concomitant serotonergic therapy and considering discontinuation of linezolid and/or the serotonergic agent if serotonin toxicity develops. A prescribing decision requires an explicit interaction-management plan. Rifampin induces metabolic enzymes and transporters, reducing the effectiveness of systemic hormonal contraception and many other medicines. Orange-red body fluids are expected, but interaction review remains essential. [12] [16]

Pregnancy is not a single contraindication column. Azithromycin is recommended for chlamydia in pregnancy, with test of cure about four weeks later. Nitrofurantoin or sulfonamides can be reasonable in the first trimester if suitable alternatives are unavailable; select by culture and avoid nitrofurantoin with G6PD deficiency. Fourteen weeks is in the second trimester. Short courses of doxycycline for suspected rickettsial infection are recommended even in children under eight and have not been shown to stain teeth.

Finally, CDC finds no convincing basis for the traditional metronidazole-alcohol disulfiram mechanism, while US labeling still advises avoidance during treatment and for three days afterward. Explain this discrepancy accurately rather than teaching proven aldehyde dehydrogenase inhibition. [3] [4] [5] [6] [7]

Try it here · Checkpoint 3 of 3

Make your prediction before reading the choices. A first attempt is just a starting point.

Case 6

Show answer and explanations

A. Slow the infusion without first interrupting exposure or assessing severity (Why this does not fit)
Interrupt and assess first; symptoms may progress and anaphylaxis must be considered.
B. Record lifelong IgE-mediated anaphylaxis solely from flushing (Why this does not fit)
Flushing during rapid infusion does not by itself establish an IgE-mediated allergy.
C. Immediately replace vancomycin without documenting the reaction phenotype (Why this does not fit)
A permanent treatment change may be unnecessary for a rate-related reaction. First assess and characterize it, then decide on safe re-administration or an alternative.
D. Stop infusion; assess airway, breathing and circulation (Best answer)
A rate-related reaction is likely, but assessment comes before deciding whether slower re-administration is appropriate.

Takeaway: Assess the reaction first; distinguish rate-related symptoms from anaphylaxis.

Case sources: [11]

Apply the organism, compartment and patient constraints

Case 2

Show answer and explanations

A. Production of a beta-lactamase that hydrolyzes amoxicillin (Why this does not fit)
This explains resistance in some walled bacteria; Mycoplasma lacks the target structure itself.
B. An altered transpeptidase with low affinity for amoxicillin (Why this does not fit)
Target alteration occurs in other bacteria, but Mycoplasma lacks peptidoglycan rather than having a resistant wall-synthesis enzyme.
C. Reduced entry through outer-membrane porins (Why this does not fit)
Porin loss can restrict beta-lactams in Gram-negative bacteria. The defining problem here is the missing peptidoglycan wall.
D. The organism lacks the peptidoglycan target of amoxicillin (Best answer)
Mycoplasma lacks a cell wall, so a PBP-directed antibiotic has no useful target.

Takeaway: Missing target and inadequate intracellular activity are different mechanisms.

Case sources: [38] [33]

Case 3

Show answer and explanations

A. Cefazolin (Why this does not fit)
Cefazolin has a much narrower useful spectrum and does not cover this isolate's species.
B. Ceftaroline (Why this does not fit)
Its MRSA activity does not make it an antipseudomonal cephalosporin.
C. Ceftazidime (Best answer)
Ceftazidime has antipseudomonal activity. The isolate still needs to test susceptible before targeted use.
D. Ceftriaxone (Why this does not fit)
Ceftriaxone is useful for many urinary pathogens but does not provide dependable Pseudomonas coverage.

Takeaway: Within a generation, the named cephalosporin matters.

Case sources: [1] [18] [33]

Case 4

Show answer and explanations

A. This approval establishes ceftobiprole for every form of prosthetic-valve endocarditis (Why this does not fit)
An indication including right-sided endocarditis does not establish unrestricted use in all prosthetic-valve disease.
B. It is an FDA-approved MRSA-active cephalosporin with an adult S. aureus bacteremia indication (Best answer)
The 2024 approval includes adult S. aureus bacteremia, including right-sided endocarditis, and includes MRSA.
C. Ceftaroline is the only cephalosporin with MRSA activity (Why this does not fit)
That older exception list is incomplete after ceftobiprole approval.
D. Its pneumonia indication also establishes treatment of MRSA CABP (Why this does not fit)
The CABP indication lists methicillin-susceptible S. aureus. The MRSA bacteremia indication cannot be transferred to pneumonia.

Takeaway: An updated exception is still an agent-specific exception.

Case sources: [2] [30]

Case 5

Show answer and explanations

A. PBP2a production with low affinity for most beta-lactams (Best answer)
mecA encodes the altered binding protein underlying methicillin resistance; prosthetic infection also needs specialist and source-control assessment.
B. Production of a penicillinase that hydrolyzes penicillin G (Why this does not fit)
Penicillinase explains penicillin resistance but does not explain the mecA-mediated resistance to nafcillin.
C. A D-Ala-D-Lac wall terminus encoded by vanA (Why this does not fit)
That alteration explains a vancomycin-resistance mechanism, not the mecA result.
D. Methylation of 23S ribosomal RNA (Why this does not fit)
Ribosomal methylation concerns macrolide-lincosamide resistance, not the altered PBP encoded by mecA.

Takeaway: mecA changes the target; a prosthetic valve prevents reducing care to one drug name.

Case sources: [27] [28]

Case 7

Show answer and explanations

A. Add calcium at the same time as each ciprofloxacin dose (Why this does not fit)
Calcium does not treat this toxicity and can reduce antibiotic absorption when coadministered.
B. Increase prednisone to counteract the antibiotic reaction (Why this does not fit)
Corticosteroid exposure is a tendon-injury risk factor, not the corrective therapy here.
C. Stop ciprofloxacin, avoid tendon loading and arrange assessment and alternative treatment (Best answer)
New tendon pain during fluoroquinolone exposure, especially with corticosteroids, warrants stopping the drug and protecting the tendon.
D. Continue ciprofloxacin because tendon injury occurs only after treatment ends (Why this does not fit)
Tendon symptoms can occur during treatment; waiting for completion risks worsening injury.

Takeaway: Fluoroquinolone tendon pain is an actionable adverse effect.

Case sources: [19]

Case 8

Show answer and explanations

A. Cefazolin (Why this does not fit)
Changing to another cephalosporin does not resolve intrinsic Listeria resistance to the class.
B. Ampicillin (Best answer)
Older age increases Listeria risk, and ampicillin supplies activity missing from cephalosporin-based treatment.
C. Azithromycin (Why this does not fit)
Atypical respiratory coverage does not supply the needed empiric Listeria meningitis treatment.
D. Metronidazole (Why this does not fit)
Anaerobic coverage does not address the organism specifically associated with this age-related gap.

Takeaway: Recognize the Listeria gap before accepting a meningitis regimen as complete.

Case sources: [23]

Case 9

Show answer and explanations

A. Oral fidaxomicin (Best answer)
Fidaxomicin is preferred for an initial nonfulminant episode when feasible, partly because of lower recurrence.
B. Intravenous vancomycin alone (Why this does not fit)
The intravenous route does not provide the needed luminal treatment of C. difficile colitis.
C. Oral metronidazole (Why this does not fit)
Fidaxomicin is preferred when accessible. Metronidazole is not preferred when fidaxomicin or oral vancomycin can be used.
D. Standard-course oral vancomycin (Why this does not fit)
Vancomycin is an acceptable alternative, but the question asks which agent is conditionally preferred when fidaxomicin is accessible.

Takeaway: Use the current C. difficile recommendation and the correct intestinal route.

Case sources: [8]

Case 10

Show answer and explanations

A. Bilirubin displacement as the main cause of the acute gray syndrome (Why this does not fit)
Bilirubin displacement is a distinct neonatal drug concern. Chloramphenicol gray syndrome reflects excessive exposure with immature clearance.
B. IgE-mediated anaphylaxis immediately after the first exposure (Why this does not fit)
Anaphylaxis can cause collapse, but the described syndrome during neonatal chloramphenicol treatment points to accumulation; resuscitation still includes evaluation for competing causes.
C. Dose-independent aplastic anemia as the cause of immediate collapse (Why this does not fit)
Aplastic anemia is a separate serious chloramphenicol toxicity, not the mechanism of this characteristic acute neonatal gray syndrome.
D. Accumulation because neonatal metabolism and elimination are immature (Best answer)
Limited clearance can produce high chloramphenicol exposure and gray syndrome; the presentation still requires emergency evaluation.

Takeaway: Connect neonatal physiology to drug accumulation without overlooking sepsis.

Case sources: [14]

Case 11

Show answer and explanations

A. Declare linezolid impossible in every circumstance regardless of infection severity (Why this does not fit)
The current label calls for assessment and monitoring of concomitant serotonergic therapy, not an unconditional prohibition.
B. Continue sertraline and wait for fever before reviewing the interaction (Why this does not fit)
Waiting for clinical toxicity omits anticipatory assessment and monitoring of a known interaction.
C. Assess the interacting therapy, counsel and monitor closely, with a plan to stop causative drugs if serotonin toxicity develops (Best answer)
Current labeling advises monitoring during concomitant use and considering discontinuation of linezolid and/or serotonergic agents when toxicity appears. Whether to interrupt sertraline in advance is a clinical decision, not an automatic prerequisite stated in this label.
D. Separate linezolid and sertraline administration by two hours (Why this does not fit)
Dose spacing does not eliminate overlapping pharmacodynamic MAO inhibition and serotonergic effects.

Takeaway: An important interaction requires a management decision, not an unsupported absolute.

Case sources: [12]

Case 12

Show answer and explanations

A. A pure vancomycin infusion reaction (Why this does not fit)
No infusion-timed flushing is described, and that reaction does not explain this combined renal and auditory pattern.
B. Aminoglycoside nephrotoxicity and ototoxicity (Best answer)
Kidney injury and auditory symptoms are characteristic exposure-related aminoglycoside toxicities and require prompt reassessment.
C. Progression of sepsis as the sole explanation for both findings (Why this does not fit)
Sepsis can cause AKI, but new tinnitus and high-frequency hearing loss during gentamicin make drug toxicity a crucial unifying concern.
D. Isolated age-related hearing loss with unrelated dehydration (Why this does not fit)
Those conditions are possible separately, but the concurrent new findings during gentamicin require evaluation for its linked toxicities.

Takeaway: Monitor aminoglycoside exposure and toxicity in both kidney and inner ear.

Case sources: [13]

Case 13

Show answer and explanations

A. Azithromycin; test of cure about four weeks after treatment (Best answer)
Azithromycin is recommended in pregnancy, and a test of cure is needed because persistent infection has maternal and neonatal consequences.
B. Doxycycline; no follow-up testing needed during the pregnancy (Why this does not fit)
Doxycycline is contraindicated in the second and third trimesters in this guidance, and pregnancy requires test of cure.
C. Metronidazole; obtain a culture only if the patient develops fever (Why this does not fit)
Metronidazole treats other genital infections but does not provide recommended chlamydia therapy.
D. Cefazolin; repeat the NAAT the day after giving treatment (Why this does not fit)
Cefazolin is not the recommended regimen, and immediate repeat NAAT can detect residual nucleic acids.

Takeaway: Pregnancy changes both chlamydia treatment and follow-up.

Case sources: [7]

Case 14

Show answer and explanations

A. Oral amoxicillin alone (Why this does not fit)
This patient is high risk, and amoxicillin alone lacks the required empiric antipseudomonal coverage.
B. Intravenous vancomycin alone (Why this does not fit)
Vancomycin misses the Gram-negative organisms that make prompt antipseudomonal treatment essential.
C. Intravenous ceftriaxone (Why this does not fit)
Ceftriaxone lacks dependable Pseudomonas activity and does not meet the empiric antipseudomonal requirement.
D. Intravenous cefepime (Best answer)
High-risk febrile neutropenia requires prompt intravenous antipseudomonal beta-lactam therapy.

Takeaway: Start adequate antipseudomonal therapy promptly in high-risk febrile neutropenia.

Case sources: [21]

Case 15

Show answer and explanations

A. The US label has no alcohol-related precaution (Why this does not fit)
The cited label still advises avoidance during treatment and for three days afterward.
B. The recommendation differs because CDC requires a longer abstinence period than the label (Why this does not fit)
CDC questions the evidence for the interaction, whereas the label advises avoidance during treatment and for three days afterward.
C. CDC finds the disulfiram mechanism unsubstantiated; the US label advises avoidance (Best answer)
The sources differ. Counseling can acknowledge that difference without falsely asserting proven aldehyde dehydrogenase inhibition.
D. Metronidazole is proven to inhibit aldehyde dehydrogenase exactly like disulfiram (Why this does not fit)
CDC explicitly challenges this traditional mechanistic claim.

Takeaway: Distinguish evidence about a mechanism from a persisting label precaution.

Case sources: [4] [5]

Case 16

Show answer and explanations

A. Stop every tuberculosis drug when urine turns orange (Why this does not fit)
Orange-red discoloration is expected with rifampin and does not itself establish dangerous toxicity.
B. Use suitable additional or alternative nonhormonal contraception (Best answer)
Rifampin induces drug-metabolizing enzymes and transporters and can lower systemic hormonal contraceptive effectiveness.
C. Contraceptive hormone concentrations predictably rise (Why this does not fit)
Enzyme induction generally increases clearance of affected hormones rather than causing this rise.
D. Take the contraceptive and rifampin two hours apart to eliminate the interaction (Why this does not fit)
This is sustained enzyme induction, not a simple intestinal binding interaction resolved by dose spacing.

Takeaway: Enzyme induction cannot be corrected merely by spacing doses.

Case sources: [16]

Case 17

Show answer and explanations

A. Start doxycycline promptly despite age under eight (Best answer)
Suspected rickettsial disease warrants doxycycline at any age; short courses have not been shown to cause tooth staining.
B. Delay treatment until antibody testing confirms the diagnosis (Why this does not fit)
Early tests may be negative, and treatment delay in suspected RMSF can be dangerous.
C. Use amoxicillin solely because the child is young (Why this does not fit)
Amoxicillin does not provide effective RMSF treatment, so age-based substitution is inappropriate.
D. Use chloramphenicol routinely because it is safer in young children (Why this does not fit)
Chloramphenicol has substantial toxicity and is not the routine preferred substitute for doxycycline.

Takeaway: The pediatric tetracycline warning has an essential doxycycline-rickettsial exception.

Case sources: [3] [14]

Case 18

Show answer and explanations

A. Nitrofurantoin is prohibited throughout pregnancy (Why this does not fit)
ACOG does not impose a blanket pregnancy prohibition; selection depends on context and alternatives.
B. The same choice is adequate if high fever and costovertebral angle tenderness develop (Why this does not fit)
Those findings suggest pyelonephritis, for which nitrofurantoin has inadequate renal tissue levels.
C. Empiric amoxicillin is always preferable regardless of the culture (Why this does not fit)
Resistance and culture results matter; amoxicillin is not automatically the better choice.
D. Nitrofurantoin is a reasonable targeted option for this lower urinary infection (Best answer)
The symptoms localize to the bladder, the isolate is susceptible, and 14 weeks is in the second trimester.

Takeaway: Use gestational timing, site and susceptibility rather than a blanket pregnancy rule.

Case sources: [6]

Case 19

Show answer and explanations

A. Nitrofurantoin because the infection began in the urinary tract (Why this does not fit)
A bladder-concentrating drug cannot substitute for adequate bloodstream treatment.
B. Ceftriaxone despite the ESBL result (Why this does not fit)
ESBL production commonly compromises third-generation cephalosporins, making this a poor definitive choice.
C. Meropenem (Best answer)
A carbapenem is preferred for ESBL bacteremia, and critical illness with hypoalbuminemia favors meropenem or imipenem over ertapenem.
D. Ertapenem solely because all carbapenems have identical pharmacokinetics (Why this does not fit)
Ertapenem protein binding and exposure concerns matter in critical illness and hypoalbuminemia.

Takeaway: An anatomic origin in urine does not make bacteremia a simple bladder infection.

Case sources: [1]

Case 20

Show answer and explanations

A. Cefepime (Why this does not fit)
Cefepime can treat susceptible Pseudomonas; this isolate's result supports its activity.
B. Ertapenem (Best answer)
Ertapenem lacks dependable Pseudomonas activity, unlike susceptible isolates treated with meropenem or imipenem.
C. Meropenem (Why this does not fit)
Meropenem can treat susceptible Pseudomonas; the stem asks for the carbapenem with the characteristic gap.
D. Imipenem-cilastatin (Why this does not fit)
Imipenem can have antipseudomonal activity when the isolate is susceptible.

Takeaway: Do not generalize antipseudomonal activity to ertapenem.

Case sources: [1] [18]

Case 21

Show answer and explanations

A. Pulmonary surfactant inhibits its antibacterial activity (Best answer)
Daptomycin can be useful in selected bloodstream infections but is not an alveolar pneumonia drug.
B. Lack of in vitro activity against susceptible MRSA (Why this does not fit)
Daptomycin has activity against susceptible MRSA. Surfactant inhibition makes the infected compartment decisive.
C. Failure to achieve any systemic exposure after intravenous dosing (Why this does not fit)
IV daptomycin achieves systemic exposure and can treat bloodstream infections; that does not overcome alveolar surfactant inhibition.
D. Bacterial beta-lactamase hydrolysis of daptomycin (Why this does not fit)
Daptomycin is a lipopeptide, not a beta-lactam. Surfactant inhibition explains the stated pneumonia limitation.

Takeaway: Activity against the organism must still work in the infected compartment.

Case sources: [17] [43]

Case 22

Show answer and explanations

A. Assume erythromycin restores clindamycin activity (Why this does not fit)
Erythromycin induces the resistance phenotype in this test; it does not rescue treatment.
B. Interpret the test as proof of vanA-mediated resistance (Why this does not fit)
The D-test examines inducible clindamycin resistance, not altered vancomycin wall binding.
C. Ignore the test if the abscess has been drained (Why this does not fit)
Drainage is important but does not change the isolate's antibiotic susceptibility interpretation.
D. Treat the isolate as clindamycin resistant (Best answer)
A positive D-test exposes inducible resistance that can undermine clindamycin despite initial apparent susceptibility.

Takeaway: An inducible resistance test can overrule an apparently susceptible initial result.

Case sources: [29] [10]

Case 23

Show answer and explanations

A. Cefazolin is a dependable replacement for enterococci (Why this does not fit)
Cephalosporins alone do not provide dependable enterococcal treatment.
B. Vancomycin resistance implies identical resistance to every protein-synthesis inhibitor (Why this does not fit)
Different antibiotic targets mean this inference is invalid; the reported linezolid susceptibility is relevant.
C. Linezolid may be an active option after site, patient and interaction assessment (Best answer)
Linezolid has activity against selected VRE infections, but susceptibility does not replace assessment of the clinical syndrome.
D. Higher vancomycin exposure always overcomes vanA resistance safely (Why this does not fit)
VanA can markedly reduce target affinity; simply increasing exposure is neither reliable nor safe.

Takeaway: VRE requires an active alternative, not an assumption that vancomycin sometimes suffices.

Case sources: [12] [28]

Case 24

Show answer and explanations

A. Cephalexin alone without drainage (Why this does not fit)
An antibiotic can address susceptible bacteria but does not evacuate a fluctuant pus collection.
B. Incision and drainage, with antibiotic need assessed from severity and host factors (Best answer)
A drainable purulent collection needs drainage; antibiotics may be added when clinically indicated.
C. Escalate to meropenem while leaving the collection intact (Why this does not fit)
Broader coverage does not evacuate a localized pus collection.
D. TMP-SMX alone without drainage (Why this does not fit)
Even an MRSA-active antibiotic does not replace source control for a drainable abscess.

Takeaway: Source control is a treatment decision, not an optional consequence of antibiotic failure.

Case sources: [10]

Case 25

Show answer and explanations

A. Penicillin plus clindamycin alongside ongoing surgical management (Best answer)
Penicillin treats the susceptible organism while clindamycin supports toxin suppression; surgery remains essential.
B. Oral doxycycline alone after the first incision (Why this does not fit)
This does not provide the recommended definitive treatment for severe documented group A streptococcal disease.
C. Metronidazole alone because all necrotic tissue implies anaerobic infection (Why this does not fit)
Necrosis does not change the documented organism into an obligate anaerobe.
D. Stop further surgical assessment once a susceptible culture returns (Why this does not fit)
Susceptibility does not establish complete source control or eliminate further debridement needs.

Takeaway: Documented group A streptococcal necrotizing infection needs both operative and antibiotic treatment.

Case sources: [10]

Case 27

Show answer and explanations

A. Sepsis-associated encephalopathy without medication contribution (Why this does not fit)
Sepsis remains a differential diagnosis, but the timing, renal decline and myoclonus require urgent consideration of cefepime exposure.
B. Uremic encephalopathy as the established sole diagnosis (Why this does not fit)
Renal disease can cause encephalopathy, but it also increases cefepime exposure. Do not exclude the medication before evaluation.
C. Cefepime-associated neurotoxicity (Best answer)
Renal impairment can increase exposure, and encephalopathy with myoclonus or seizures is a recognized toxicity.
D. Acute stroke as the established cause of all findings (Why this does not fit)
Stroke may require exclusion based on examination, but the exposure-linked diffuse encephalopathy and myoclonus make cefepime toxicity important.

Takeaway: Changing renal function requires repeated assessment of renally cleared antibiotic dosing.

Case sources: [18]

Case 28

Show answer and explanations

A. Acute tubular injury from an aminoglycoside (Why this does not fit)
Nephrotoxic AKI can cause hyperkalemia, but no aminoglycoside was added; trimethoprim directly impairs potassium excretion.
B. Reduced renal potassium excretion from trimethoprim adds to the risk (Best answer)
Kidney disease and lisinopril amplify concern for trimethoprim-associated hyperkalemia, which requires prompt management.
C. Increased intestinal potassium absorption as trimethoprim's main action (Why this does not fit)
The recognized mechanism involves distal renal potassium handling, not increased intestinal absorption.
D. A laboratory artifact caused by an isolated creatinine rise (Why this does not fit)
Trimethoprim can increase creatinine by affecting tubular secretion, but it can also cause real hyperkalemia. The potassium result requires prompt assessment.

Takeaway: TMP-SMX monitoring depends on kidney function and concurrent potassium-raising drugs.

Case sources: [15]

Case 29

Show answer and explanations

A. Additional risk of QT prolongation and ventricular arrhythmia (Best answer)
Azithromycin can prolong QT, and low potassium plus another QT-prolonging drug increases vulnerability.
B. Dose-dependent renal accumulation as the main azithromycin hazard (Why this does not fit)
The supplied risks directly concern ventricular repolarization; renal accumulation is not established as the explanation.
C. Sodium-channel blockade causing isolated QRS widening (Why this does not fit)
The principal electrical concern with azithromycin is QT prolongation, particularly with low potassium and another QT-prolonging drug.
D. Vagal AV nodal slowing as the intended protective effect (Why this does not fit)
Azithromycin is not prescribed to control AV conduction. Its repolarization effect can increase ventricular arrhythmia risk.

Takeaway: Assess the patient's electrical risk, not just the infection.

Case sources: [20]

Case 30

Show answer and explanations

A. Meropenem solely because its spectrum is widest (Why this does not fit)
Routine broad Gram-negative and anaerobic coverage is not the objective of this clean orthopedic prophylaxis.
B. Intravenous vancomycin alone (Why this does not fit)
Vancomycin has selected prophylaxis roles, including MRSA colonization, but cefazolin is standard here with no stated allergy or known MRSA colonization.
C. Metronidazole alone (Why this does not fit)
Anaerobic-only coverage misses the skin organisms central to this procedure's prophylaxis.
D. Cefazolin (Best answer)
Cefazolin targets the usual operative skin flora and is a standard recommended agent for joint replacement prophylaxis.

Takeaway: Match prophylaxis to the procedure and likely contaminants.

Case sources: [26]

Case 31

Show answer and explanations

A. Every synergistic regimen must contain gentamicin regardless of kidney function (Why this does not fit)
Synergy is not synonymous with an obligatory aminoglycoside.
B. The evidence proves randomized equivalence in all Enterococcus species (Why this does not fit)
The cited comparative study was observational and concerned E. faecalis, not every enterococcal infection.
C. Synergy without an aminoglycoside in selected enterococcal endocarditis (Best answer)
Clinical comparative evidence supports the combination in appropriate E. faecalis disease, reducing reliance on nephrotoxic gentamicin.
D. Ceftriaxone alone reliably eradicates enterococcal endocarditis (Why this does not fit)
The combination's role does not establish ceftriaxone monotherapy as dependable enterococcal treatment.

Takeaway: Preserve the species, combination and evidence limits when applying synergy.

Case sources: [25]

Case 32

Show answer and explanations

A. Aminoglycoside-mediated auditory injury (Why this does not fit)
Auditory toxicity belongs to a different class and does not explain ceftriaxone's neonatal bilirubin/calcium restrictions.
B. Bilirubin displacement and ceftriaxone-calcium precipitation (Best answer)
Both the bilirubin status and intravenous calcium exposure are relevant contraindication concerns in this neonate.
C. Immature glucuronidation causing chloramphenicol gray syndrome (Why this does not fit)
That is a different neonatal drug toxicity; ceftriaxone poses bilirubin displacement and calcium-precipitation concerns.
D. Reduced oral bioavailability in premature infants (Why this does not fit)
Ceftriaxone is administered parenterally. The relevant hazards occur despite adequate systemic drug delivery.

Takeaway: Neonatal safety is drug-specific and cannot be inferred from cephalosporin generation.

Case sources: [24]

Sources

IDSA 2026 Guidance on Treatment of Antimicrobial Resistant Gram-Negative Infections (2026-07-30)
ESBL treatment by site and severity, oral transition prerequisites, and organism-specific resistance decisions.
FDA approval of ceftobiprole for three indications (2024-04-03)
Ceftobiprole is an additional MRSA-active cephalosporin; its indications are not interchangeable with every cephalosporin.
CDC: Research on doxycycline and tooth staining (2024-05-15)
Short-course doxycycline for suspected rickettsial disease in children of all ages.
CDC STI Treatment Guidelines: Bacterial Vaginosis (2021)
Evidence does not support the traditional metronidazole-alcohol acetaldehyde mechanism.
Metronidazole tablets prescribing information
Anaerobic activation and DNA injury; current labeling still advises avoiding alcohol during treatment and for three days afterward.
ACOG Clinical Consensus: Urinary Tract Infections in Pregnant Individuals (2023)
Pregnancy cystitis therapy, conditional first-trimester use of nitrofurantoin or sulfonamides, and inadequate renal tissue activity of nitrofurantoin.
CDC STI Treatment Guidelines: Chlamydial Infections (2021)
Azithromycin in pregnancy, test of cure at approximately four weeks, and doxycycline pregnancy restrictions.
IDSA/SHEA Focused Update: Clostridioides difficile Infection (2021)
Fidaxomicin preference with oral vancomycin acceptable for an initial nonfulminant episode; distinct fulminant treatment.
ATS/IDSA Guideline: Community-Acquired Pneumonia in Adults (2019)
CAP regimens, macrolide resistance threshold, and no routine additional anaerobic coverage for aspiration without abscess or empyema.
IDSA Guideline: Skin and Soft Tissue Infections (2014)
Abscess drainage, streptococcal cellulitis coverage, urgent surgery and penicillin plus clindamycin for documented group A streptococcal necrotizing fasciitis.
Vancomycin injection prescribing information
Cell-wall substrate binding, Gram-positive activity and infusion-associated reactions that may include severe hypotension.
Linezolid prescribing information
Initiation-complex inhibition, VRE activity, weekly CBC monitoring and management of serotonergic interactions.
Gentamicin prescribing information
Aminoglycoside pharmacology, nephrotoxicity, ototoxicity and neuromuscular blockade.
Chloramphenicol sodium succinate prescribing information
Neonatal accumulation causing gray syndrome and serious marrow toxicity.
Sulfamethoxazole and trimethoprim prescribing information
Sequential folate inhibition, hyperkalemia, serious skin reactions and hemolysis risk with G6PD deficiency.
Rifampin prescribing information
RNA polymerase inhibition, induction of metabolic enzymes and transporters, and contraceptive interaction.
Daptomycin prescribing information
Membrane action, Gram-positive indications, creatine kinase monitoring and lack of a pneumonia indication.
Cefepime prescribing information
Antipseudomonal activity, renal dose adjustment and encephalopathy, myoclonus or seizures with neurotoxicity.
Ciprofloxacin prescribing information
DNA gyrase/topoisomerase inhibition, tendon injury, chelation and major fluoroquinolone adverse effects.
Azithromycin prescribing information
50S binding, methylation-mediated resistance and QT prolongation.
ASCO/IDSA 2018 Outpatient Management of Fever and Neutropenia guideline update (2018)
Official guideline repeats inpatient antipseudomonal beta-lactam recommendations for patients inappropriate for outpatient treatment; prompt therapy and specific indications for additional agents.
ATS/IDSA Guideline: Hospital-Acquired and Ventilator-Associated Pneumonia (2016)
Risk-based MRSA and resistant Gram-negative coverage, local antibiogram use and de-escalation.
WHO Guidelines on Meningitis Diagnosis, Treatment and Care (2025)
Empiric bacterial meningitis therapy and additional ampicillin or amoxicillin for Listeria risk including age over 60, pregnancy or immunocompromise.
Ceftriaxone prescribing information
PBP inhibition and contraindications involving hyperbilirubinemic neonates and neonatal intravenous calcium.
Ampicillin plus ceftriaxone versus ampicillin plus gentamicin for E. faecalis endocarditis (2013)
Primary comparative cohort supporting an aminoglycoside-sparing combination; not a randomized equivalence trial.
ASHP/IDSA/SIS/SHEA Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery (2013)
Procedure-specific prophylaxis and cefazolin for common clean orthopedic procedures with implantation.
CDC Laboratory Testing for MRSA (2025-06-27)
mecA and PBP2a mechanism. Its exception list omits ceftobiprole, so FDA source 2 supersedes that portion.
CDC Laboratory Testing for Vancomycin-Resistant S. aureus (2024-04-15)
vanA-mediated resistance and distinction from methicillin resistance.
Contrasting Pediatric and Adult Methicillin-resistant S. aureus Isolates (2006)
Primary surveillance report explaining D-test interpretation for erythromycin-resistant, apparently clindamycin-susceptible isolates.
Zevtera prescribing information
MRSA-active ceftobiprole: adult bacteremia and right-sided endocarditis; CABP indication lists methicillin-susceptible S. aureus, not MRSA.
Doxycycline hyclate prescribing information
30S target, polyvalent-cation absorption interactions and photosensitivity.
Imipenem and cilastatin prescribing information
Cilastatin inhibits renal dehydropeptidase; seizure risk, renal adjustment and beta-lactam hypersensitivity.
Medical Microbiology, fourth edition: Antimicrobial Chemotherapy (1996)
Stable basic antibiotic target, uptake and resistance mechanisms only; historical treatment recommendations are not adopted.
Cloning and Expression of M. tuberculosis and M. leprae Dihydropteroate Synthase in E. coli (2000)
Primary laboratory evidence for dapsone inhibition of bacterial dihydropteroate synthase.
CDC Yellow Book: Travelers' Diarrhea
Metronidazole activity in Giardia and invasive E. histolytica; amebiasis also needs a luminal agent.
ACG Guideline Highlights: Treatment of Helicobacter pylori Infection (2024)
Metronidazole is one component of bismuth quadruple eradication therapy, not H. pylori monotherapy.
Enterococcal Disease, Epidemiology, and Implications for Treatment (2014)
Species-specific enterococcal susceptibility and ampicillin-based treatment; quinupristin-dalfopristin lacks E. faecalis activity.
Medical Microbiology, fourth edition: Structure (1996)
Gram-positive and Gram-negative envelopes, outer membrane LPS barrier and wall-less Mycoplasma.
American Dental Association: Antibiotics for Dental Pain and Swelling Guideline (2019)
Definitive dental care and drainage for localized pulpal/periapical disease in adults without severe immunocompromise; antibiotics with systemic involvement.
NICE NG195: Meningitis in babies in neonatal units (2021)
Neonatal-unit meningitis with unknown pathogen: IV amoxicillin and cefotaxime under the UK guideline; not a universal neonatal sepsis regimen.
Erythromycin prescribing information
CYP3A inhibition and gastrointestinal adverse effects; avoid treating macrolide interaction profiles as identical.
ACG Clinical Guideline: Gastroparesis (2022)
Macrolide motilin-receptor effects including erythromycin; limited short-term prokinetic use is distinct from antibiotic selection.
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact (2005)
Primary experimental report, abstract read: pulmonary surfactant inhibits daptomycin antibacterial activity. Animal-model distinctions do not authorize pneumonia treatment.

Return to lesson title